|
Objective: To observe the animal model of acute liver failure in the application of anti-endotoxin anti-Chinese medicine compound capillaris side effect of the treatment of endotoxemia. Endotoxemia observed therapy combined with anti-Western medicine treatment of chronic severe hepatitis B clinical efficacy. Methods: The experimental rats were divided into four groups (normal control group, poisoning treatment group, prevention plus treatment group) to prepare D-galactosamine model of acute liver failure, and the treatment group and the untreated group in order to prevent resistance to internal Toxin Treatment of Traditional Chinese Medicine Compound capillaris, dynamic observation of four experimental rat plasma endotoxin (ET) levels in plasma endotoxin (ET) and plasma lipid peroxidation (LPO), plasma fibronectin (Fn) levels relationships and liver pathology. Infectious Diseases Hospital in Tianjin hepatitis Division from June 2009 to December 2009 with chronic severe hepatitis B treated 63 patients for the study, according to a 2:1 ratio 42 cases were randomly divided into treatment group and control group 21 cases, control group based on Western medicine treatment and symptomatic and supportive treatment, the treatment group were treated based on the combined oral compound capillaris parties and TCM retention enema for 8 weeks. Observed in patients treated for 8 weeks total mortality, survival curves for 2 weeks when clinical symptoms, before treatment, 2 weeks, 4 weeks, 6 weeks and 8 weeks prothrombin time international normalized ratio (INR ), total bilirubin (TBiL), albumin (ALB), cholinesterase (CHE) as well as end-stage liver disease (MELD) score changes, before treatment and 4 weeks, ET, tumor necrosis factor-α (TNF -α), LPO levels, as well as the treatment group during treatment adverse events. Results: The injection of D-galactosamine 24 hours after the occurrence of both endotoxemia, compared with normal control group difference was statistically significant (P lt; 0.01). Poisoned rats 24,36,48 hours in plasma ET levels increased gradually, peaked at 60 hours, 72 hours a downward trend. The treatment group compared with the right poisoning each phase ET group were lower than intoxication. Prevention plus treatment group compared with the treatment group, each time the treatment group were lower than the level of ET. LPO poisoning group than the treatment group, prevention plus treatment group at each time were lower than LPO poisoning group, 24,36,60 hours were lower than the treatment group. Experimental groups 24 hours after the poisoning Fn levels were down slightly compared with the normal control group, the difference was statistically significant (P lt; 0.01), 72 小时 poisoning group Fn prevention and treatment group and untreated group differences were statistically significant (all P lt; 0.01). Pathological changes of liver injury prevention plus treatment group lightest in the treatment group, followed by poisoning group heaviest. Two groups of patients died eight weeks of the treatment period, 20 cases in which the treatment group of 11 patients in the control group, 9 patients. 26.2% in the treatment group, the total mortality, total mortality rate of 42.9% in control group. Treatment group during treatment survival rates were higher. 2 weeks of treatment, the patients were fatigue, bloating, loss of appetite than before treatment improved in patients treated with fatigue, loss of appetite, improved compared with the control group, the differences were statistically significant (all P lt; 0.05). Two groups of patients before treatment, the INR, TBiL, ALB, CHE, MELD score, ET, TNF-α, LPO consistent baseline, the difference was not statistically significant (all P gt; 0.05). With the increase in number of weeks of treatment, patients were INR value, TBiL levels and MELD score gradually declined, ALB, CHE levels have increased, from treatment for 2 weeks from the time the treatment group compared with the control group TBiL level difference was statistically significant ( both P lt; 0.05), starting from week 4 of treatment in patients treated with INR values, MELD score compared with the control group, the differences were statistically significant (all P lt; 0.05). After 8 weeks, patients treated with ALB levels compared with the control group there was significant difference (P lt; 0.05). Treatment for 2 weeks, 4 weeks, 6 weeks and 8 weeks treatment group and the control group of patients with CHE level difference was not statistically significant (P gt; 0.05). All Group 2 patients before treatment occurred endotoxemia, ET levels were 160pg/ml or more. After 4 weeks, patients treated with ET, TNF-α and decreased LPO levels than before treatment and were lower than the control group. Treatment group ET, TNF-α and LPO levels compared with the control group difference was statistically significant (both p lt; 0.05). Treatment group did not occur during treatment with application of compound capillaris parties and containing Rhubarb retention-enema treatment-related adverse reactions. Conclusion: The application of anti-endotoxin treatment of traditional Chinese medicine compound capillaris parties can significantly reduce acute liver failure animal blood ET, LPO level, improve plasma Fn levels, reduce degree of liver injury in experimental animals, indicating that compound capillaris inner side has a clear anti- toxin, anti-lipid peroxidation and protective effect of liver cells. In giving D-galactosamine before modeling plus anti-endotoxin Chinese medicine compound capillaris square prevention, treatment of endotoxemia can make better efficacy. Anti-endotoxin therapy combined with Western medicine treatment of chronic severe hepatitis B patients, compared with Western medicine alone can more effectively reduce mortality and improve clinical symptoms, more effectively reduce the ET, TNF-α, LPO, TBiL, INR values, and MELD score improve ALB level, with anti-endotoxin, lipid oxidation, reduce inflammation and necrosis of the liver, the liver synthesis of reserve capacity, improve coagulation disorders and other effects, the clinical treatment of chronic severe hepatitis B an effective and workable solutions.
|